Actively Recruiting
Evaluating QL1706 with Chemotherapy for Advanced Endometrial Cancer After PD-1L1 Therapy Failure
Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2026-10-16
30
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of QL1706 with chemotherapy, with or without bevacizumab, in patients who have advanced recurrent or metastatic endometrial cancer that has progressed after previous treatment with PD-1L1 inhibitors. This Phase II study aims to assess the effectiveness and safety of this treatment approach in patients who have limited options due to prior therapy failure. Participants receive QL1706 intravenously every three weeks at a dose of 5 mgkg, along with physicians choice chemotherapy for 3 to 6 cycles. Bevacizumab may also be given optionally every three weeks at 15 mgkg. Treatment continues until disease progression, unacceptable side effects, completion of one year of treatment, or meeting other discontinuation criteria. The study includes three phases screening, treatment, and post-treatment follow-up, with ongoing safety monitoring. During the study, participants undergo evaluations including tumor assessments to measure response rates and disease progression. Safety is closely monitored through adverse event recording. After treatment ends, participants are followed for safety and survival outcomes for up to five years. Additional follow-up occurs if treatment stops for reasons other than progression or death. This comprehensive monitoring aims to understand the long-term effects and outcomes of the treatment combination.
CONDITIONS
Brief Title
QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
Research Team
W
Wen X Liu, Doctor
L
Lu Sun
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here